Osimertinib is currently approved in 84 countries, for the treatment of patients with locally advanced or metastatic EGFR T790M mutation‐positive NSCLC, and in 75 countries for use as first‐line treatment of patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletion or p.Leu858Arg EGFR mutations (with country‐specific variations).7, 8, 9. Here, EGFR is linked to non-small cell lung carcinoma.